Need for an Update for the Guideline for the Management of Mild Cognitive Impairment

Oct 6, 2026

Uploaded by Connor

Attention is focused on diagnosing and treating mild cognitive impairment (MCI) since early recognition and preventive management can slow Alzheimer’s disease progression. Biomarker use for predicting conversion into dementia is increasingly feasible in medical practice. Authors propose guideline update considerations, including predictable biomarkers, reconsideration of cholinesterase inhibitor use after additional trials, and structured lifestyle intervention regimens. Review of three MCI patients supported non-recommendation of cholinesterase inhibitors and highlighted caregiver concerns about maintaining exercise and cognitive training.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages10

Reading Time25 min

AccessFree to download

Abstract

Introduction

Background on β-amyloid and tau

Study aims and guideline comparison

Case Report

Patient information and diagnostic assessment

Dement Neurocogn Disord. 2022 Oct;21(4):107-116 [https://doi.org/10.12779/dnd.2022.21.4.107](https://doi.org/10.12779/dnd.2022.21.4.107)[ ](https://doi.org/10.12779/dnd.2022.21.4.107)pISSN 1738-1495·eISSN 2384-0757 Editorial Received: Jul 6, 2022 Revised: Sep 12, 2022 Accepted: Sep 13, 2022 Published online: Oct 25, 2022 Correspondence to So Young Moon Department of Neurology, Ajou University School of Medicine, 164 Worldcup-ro, Yeongtong-gu, Suwon 16499, Korea. Email: [symoon.bv@gmail.com](symoon.bv@gmail.com) © 2022 Korean Dementia Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ORCID iDs Minji Kim [https://orcid.org/0000-0003-3340-8603](https://orcid.org/0000-0003-3340-8603)[ ](https://orcid.org/0000-0003-3340-8603)So Young Moon [https://orcid.org/0000-0002-1025-1968](https://orcid.org/0000-0002-1025-1968) Funding This work was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and Korea Dementia Research Center (KDRC), funded by the Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea (HU21C0016) . Conflict of Interest The authors have no financial conflicts of interest. Need for an Update for the Guideline for the Management of Mild Cognitive Impairment Minji Kim ,1 So Young Moon 2 1Department of Medicine, Ajou University School of Medicine, Suwon, Korea 2Department of Neurology, Ajou University School of Medicine, Suwon, Korea ABSTRACT Attention is being paid to diagnosis and treatment of mild cognitive impairment (MCI) because early diagnosis and preventive management can slow down the progression of Alzheimer’s disease. In particular, in the present era, the use of biomarkers for predicting conversion into dementia is permitted in medical practice. Therefore, authors aimed to propose additional considerations when updating guidelines for the management of MCI, including predictable biomarkers, revising treatment option after additional clinical trials for cholinesterase inhibitors, and detailed regimes for lifestyle interventions. After reviewing 3 patients with MCI by detailed evaluation, we realized that cholinesterase inhibitors were not recommended. In addition, regular exercise and cognitive training were only possible recommendations for patients according to current guidelines, although all 3 patients had evidence of β-amyloid accumulation and related neurodegeneration. Furthermore, caregivers for all 3 patients were worried whether patients could keep doing regular exercise and cognitive training by themselves and asked about the economic training system which monitors patients so that they can keep training. Therefore, we propose that guidelines for managing MCI need to be updated in the present era when the use of biomarkers for predicting conversion into dementia is permitted in medical practice. Keywords: Mild Cognitive Impairment; Guideline; Cholinesterase Inhibitors; Amyloid INTRODUCTION Currently, it is widely accepted that β-amyloid (Aβ) and pathologic tau as the most representative neuropathology in Alzheimer’s disease (AD) can accumulate from cognitively unimpaired stage and develop into mild cognitive impairment (MCI) and dementia through neurodegeneration over a couple of decades.1 Accordingly, the importance of early diagnosis and preventive management to slow down the progression of AD has been emphasized.2 Some studies have put their weight behind this emphasis on early diagnosis and prevention of dementia, showing that age-adjusted incidences of dementia have actually fallen in countries with changes in life

FAQs

Why is updating the MCI management guideline emphasized?

Early diagnosis and preventive management can slow Alzheimer’s disease progression. The document argues that guideline updates are needed in the biomarker era and to refine treatment and lifestyle recommendations.

How does the article relate biomarkers to the MCI-to-dementia pathway?

It states that β-amyloid and pathologic tau can accumulate and that biomarkers may be used to predict conversion into dementia, supporting the need for updated guidance.

What did the review of three MCI patients lead authors to conclude about cholinesterase inhibitors and lifestyle interventions?

The authors realized cholinesterase inhibitors were not recommended for these patients. They also found regular exercise and cognitive training were only possible recommendations under current guidelines, even though all three showed β-amyloid accumulation and related neurodegeneration.

Oct 6, 2026

Uploaded by Connor